RedHill Biopharma (RDHL) Change in Account Payables (2016 - 2022)

RedHill Biopharma (RDHL) has 7 years of Change in Account Payables data on file, last reported at -$554000.0 in Q4 2022.

• Change in Account Payables for Q4 2022 came in at -$554000.0, up 84.53% year-over-year; the trailing twelve-month figure through Dec 2022 was -$7.4 million (down 6797.3% YoY), and the FY2025 annual result was -$437000.0, up 79.29% from the prior year.
• Change in Account Payables declined to -$554000.0 in Q4 2022 per RDHL's latest filing, from $411000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $6.8 million in Q2 2021 and troughed at -$6.0 million in Q1 2022.
• A 5-year average of -$28750.0 and a median of -$52500.0 in 2018 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2018 and 2020: Change in Account Payables plunged 5235.9% in 2018, then soared 2372.55% in 2020.
• A 5-year view of Change in Account Payables shows it stood at -$543000.0 in 2018, then retreated by 12.34% to -$610000.0 in 2019, then surged by 917.05% to $5.0 million in 2020, then tumbled by 171.85% to -$3.6 million in 2021, then soared by 84.53% to -$554000.0 in 2022.
• Business Quant data shows RDHL's Change in Account Payables at -$554000.0 in Q4 2022, $411000.0 in Q3 2022, and -$1.3 million in Q2 2022.